| Host |
Rabbit |
| Klon |
SP105 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide near the internal region of human J-chain |
| Lokalisation |
Cytoplasm |
J-Chain
|
Zytomed Systems GmbH |
SP105 |
1 ml |
Concentrate |
RUO |
510-4054 |
-
|
| Host |
Mouse |
| Klon |
Mc19-9 |
| Format |
Purified |
| Methode |
F, EL, WB, IP |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Human J Chain |
J Chain
|
Zytomed Systems GmbH |
Mc19-9 |
200 µg |
Purified |
RUO |
610-0001 |
-
|
| Host |
Mouse+Rabbit |
| Klon |
L1C1+polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, bone marrow |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1+not determined |
| Lokalisation |
Cytoplasm |
Kappa + Lambda
|
Biocare Medical |
L1C1+polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API3159DSAA |
-
|
| Host |
Rabbit |
| Klon |
SP148 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Free kappa light chain from pooled human IgG kappa myeloma sera. |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zytomed Systems GmbH |
SP148 |
0.5 ml |
Concentrate |
RUO |
511-4482 |
-
|
| Host |
Rabbit |
| Klon |
SP148 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Free kappa light chain from pooled human IgG kappa myeloma sera. |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zytomed Systems GmbH |
SP148 |
1 ml |
Concentrate |
RUO |
511-4484 |
-
|
| Host |
Mouse |
| Klon |
L1C1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
| Positivkontrolle |
Tonsil or bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Biocare Medical |
L1C1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3149A |
-
|
| Host |
Mouse |
| Klon |
L1C1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
| Positivkontrolle |
Tonsil or bone marrow |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Biocare Medical |
L1C1 |
1 ml |
Concentrate |
CE/IVD |
ACI3149C |
-
|
| Host |
Mouse |
| Klon |
L1C1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Reveal modified citrate buffer pH 6.0 |
| Positivkontrolle |
Tonsil or bone marrow |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Biocare Medical |
L1C1 |
6 ml |
Ready-to-use |
CE/IVD |
API3149AA |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR015 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP025 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP025-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 - 1:500 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP025-05 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM81 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human IGKC protein |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
1 ml |
Concentrate |
CE/IVD |
Z2532ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM81 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human IGKC protein |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
7 ml |
Ready-to-use |
CE/IVD |
Z2532MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM81 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human IGKC protein |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
0.5 ml |
Concentrate |
CE/IVD |
Z2532MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM81 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Tonsil or lymph node. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human IGKC protein |
| Lokalisation |
Cytoplasm |
Kappa Light Chain
|
Zeta Corporation |
ZM81 |
0.1 ml |
Concentrate |
CE/IVD |
Z2532MT |
-
|
| Host |
Mouse |
| Klon |
KP-53 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2b |
| Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
1 ml |
Concentrate |
CE/IVD |
MOB544 |
-
|
| Host |
Mouse |
| Klon |
KP-53 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2b |
| Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
0.1 ml |
Concentrate |
CE/IVD |
MOB544-01 |
-
|
| Host |
Mouse |
| Klon |
KP-53 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
IgG2b |
| Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
0.5 ml |
Concentrate |
CE/IVD |
MOB544-05 |
-
|
| Host |
Mouse |
| Klon |
KP-53 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG2b |
| Lokalisation |
Cytoplasm |
Kappa light chain (KP-53)
|
Diagnostic Biosystems |
KP-53 |
6 ml |
Ready-to-use |
CE/IVD |
PDM055 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
Kappa Light Chain FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F001 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
Kappa Light Chain FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F001-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Lyophilised |
| Methode |
EL, WB, IHC(P) |
| Vorbehandlung |
Proteinase K |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant human KGF |
Keratinocyte Growth Factor, Recombinant Human (KGF, Fibroblast Growth Factor 7, FGF-7)
|
Zytomed Systems GmbH |
polyclonal |
100 µg |
Lyophilised |
RUO |
611-0045 |
-
|
| Host |
Mouse |
| Klon |
MIB-1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Human recombinant peptide corresponding to a 1002 bp Ki-67 cDNA fragment |
| Lokalisation |
Nucleus |
Ki-67
|
Biocare Medical |
MIB-1 |
6 ml |
Ready-to-use |
CE/IVD |
API3156AA |
-
|
| Host |
Mouse |
| Klon |
MIB-1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon cancer |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Human recombinant peptide corresponding to a 1002 bp Ki-67 cDNA fragment |
| Lokalisation |
Nucleus |
Ki-67
|
Biocare Medical |
MIB-1 |
25 ml |
Ready-to-use |
CE/IVD |
API3156H |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR048 |
-
|
| Host |
Rabbit |
| Klon |
SP6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
1 ml |
Concentrate |
CE/IVD |
RMAB004 |
-
|
| Host |
Rabbit |
| Klon |
SP6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB004-01 |
-
|
| Host |
Rabbit |
| Klon |
SP6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB004-05 |
-
|
| Host |
Rabbit |
| Klon |
SP6 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus |
Ki-67
|
Diagnostic Biosystems |
SP6 |
6 ml |
Ready-to-use |
CE/IVD |
RMPD004 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP026 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP026-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Cytoplasm |
Ki-67
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP026-05 |
-
|
| Host |
Mouse |
| Klon |
MIB-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
1.0 ml |
Concentrate |
CE/IVD |
Z2305ML |
-
|
| Host |
Mouse |
| Klon |
MIB-1 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2305MP |
-
|
| Host |
Mouse |
| Klon |
MIB-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2305MS |
-
|
| Host |
Mouse |
| Klon |
MIB-1 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
1:150 - 1:300 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Nuclear fractions of Hodgkin lymphoma cell line L248 of human origin |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
MIB-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2305MT |
-
|
| Host |
Mouse |
| Klon |
ZM67 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG/κ |
| Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
1.0 ml |
Concentrate |
CE/IVD |
Z2377ML |
-
|
| Host |
Mouse |
| Klon |
ZM67 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
- |
| Isotyp |
IgG/κ |
| Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
7 ml |
Ready-to-use |
CE/IVD |
Z2377MP |
-
|
| Host |
Mouse |
| Klon |
ZM67 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG/κ |
| Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
0.5 ml |
Concentrate |
CE/IVD |
Z2377MS |
-
|
| Host |
Mouse |
| Klon |
ZM67 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Spleen, tonsil, or breast carcinomas. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG/κ |
| Verdünnung |
Recombinant human Ki67 protein fragment (around aa2293-2478) |
| Lokalisation |
Nucleus |
Ki-67
|
Zeta Corporation |
ZM67 |
0.1 ml |
Concentrate |
CE/IVD |
Z2377MT |
-
|
| Host |
Mouse+Rabbit |
| Klon |
DVB-2+polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1+not determined |
| Lokalisation |
Nuclear and cytoplasmic |
Ki-67 + Caspase-3
|
Biocare Medical |
DVB-2+polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PPM240DSAA |
-
|
| Host |
Mouse + Rabbit |
| Klon |
MIB-1+BC1+EP17+EP30 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG/kappa + IgG |
| Lokalisation |
Nucleus and cytoplasm |
Ki-67 + CK7/8/18
|
Biocare Medical |
MIB-1+BC1+EP17+EP30 |
6 ml |
Ready-to-use |
CE/IVD |
API3192DSAA |
-
|
| Host |
Mouse |
| Klon |
H-6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Nucleus |
Ku (p70)
|
Diagnostic Biosystems |
H-6 |
1 ml |
Concentrate |
CE/IVD |
MOB557 |
-
|
| Host |
Mouse |
| Klon |
H-6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Nucleus |
Ku (p70)
|
Diagnostic Biosystems |
H-6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB557-01 |
-
|
| Host |
Mouse |
| Klon |
H-6 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 |
| Lokalisation |
Nucleus |
Ku (p70)
|
Diagnostic Biosystems |
H-6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB557-05 |
-
|
| Host |
Rabbit |
| Klon |
SP130 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to an internal region of human Ku80 protein |
| Lokalisation |
Nucleus |
Ku80
|
Zytomed Systems GmbH |
SP130 |
0.5 ml |
Concentrate |
RUO |
511-4302 |
-
|
| Host |
Rabbit |
| Klon |
SP130 |
| Format |
Concentrate |
| Methode |
P, WB |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Synthetic peptide corresponding to an internal region of human Ku80 protein |
| Lokalisation |
Nucleus |
Ku80
|
Zytomed Systems GmbH |
SP130 |
1 ml |
Concentrate |
RUO |
511-4304 |
-
|
| Host |
Mouse+Rabbit |
| Klon |
L26+SP7 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
- |
| Isotyp |
IgG2a+IgG |
| Lokalisation |
Cell membrane |
L26 + CD3
|
Biocare Medical |
L26+SP7 |
6 ml |
Ready-to-use |
CE/IVD |
PM237DSAA |
-
|
| Host |
Rabbit |
| Klon |
CAL26 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:100 |
| Isotyp |
Rabbit IgG1 |
| Lokalisation |
Cell membrane and cytoplasm |
LAG3
|
Biocare Medical |
CAL26 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3213A |
-
|